custom image

Joint meeting with: Obesity: From Cell to Patient

Diabetes: Many Faces of the Disease

February 1-3, 2021 | 10:00AM EST | 3:00PM UTC*
*Program is in development and subject to change

Advanced Filters

About Novo Nordisk

At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: rare bleeding disorders, growth hormone related disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries.

Sust. Benefactor

AstraZeneca R&D High Level Overview:

We are driven by science, united by science, and every day, we push the boundaries of science to deliver life-changing medicines.

Link for more information:

Microbial Sciences:

Our business model thrives on being dynamic and partly externalized, with a firm focus on driving science in our key areas of interest. Early, flexible partnering with the brightest and best in the world allows us to combine knowledge and progress clinical development, while managing the challenges associated with neuroscience and microbial science research.

Link for more information:


We are committed to defining new standards of care for patients with cardiovascular disease, heart failure, metabolic diseases, such as diabetes and non-alcoholic steatohepatitis (NASH), and chronic kidney disease (CKD) - improving their outcomes and decreasing mortality rates.

Link for more information:

Respiratory / Immunology:

We are aiming to transform the treatment of respiratory diseases, with our growing portfolio of inhaled combinations at the core of care, biologics for the unmet needs of specific patient populations, and scientific advancements in disease modification.

Link for more information: